Equities

Shanghai Shen Lian Biomedical Corp

688098:SHH

Shanghai Shen Lian Biomedical Corp

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CNY)5.39
  • Today's Change-0.16 / -2.88%
  • Shares traded3.76m
  • 1 Year change-30.54%
  • Beta--
Data delayed at least 15 minutes, as of Nov 14 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Shanghai Shen Lian Biomedical Corp is a China-based company mainly engaged in the research, development, production and sales of veterinary biological products. The Company is committed to the research & development of foot and mouth disease vaccines, which are used to protect animals from foot and mouth diseases. The Company's main product are swine foot and mouth disease vaccines, and it also provides cattle foot and mouth disease vaccines, other swine vaccines, and other veterinary diagnostic reagents. The Company mainly sells its products within domestic market.

  • Revenue in CNY (TTM)310.36m
  • Net income in CNY-19.73m
  • Incorporated2001
  • Employees380.00
  • Location
    Shanghai Shen Lian Biomedical CorpNo. 48Jiangchuan East Road, Minhang DistrictSHANGHAI 200241ChinaCHN
  • Phone+86 2 161257979
  • Fax+86 2 161267296
  • Websitehttp://www.slbio.com.cn/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Shanghai Shen Lian Biomedical Corp310.36m-19.73m2.28bn380.00--1.56--7.34-0.048-0.0480.75583.560.19441.160.9692816,747.00-1.485.39-1.585.8460.6677.45-7.6225.485.14--0.001238.49-8.251.85-48.41-18.4910.47--
Shanghai Serum Bio-Technology Co Ltd197.30m50.92m2.30bn321.0045.142.06--11.650.47060.47061.8210.300.17351.143.91614,647.904.4810.434.5610.8476.6080.5425.8132.5742.72--0.00464.939.145.67-39.54-1.6213.07--
Hanshang Group Co Ltd1.28bn-5.18m2.39bn2.38k--1.40--1.87-0.016-0.0164.315.800.3622.528.04536,620.30-0.44512.00-0.75013.8953.6057.24-1.234.890.26881.180.316315.030.18935.14-32.2425.6212.88--
Data as of Nov 14 2024. Currency figures normalised to Shanghai Shen Lian Biomedical Corp's reporting currency: Chinese Yuan Renminbi CNY

Institutional shareholders

2.01%Per cent of shares held by top holders
HolderShares% Held
Gfund Management Co., Ltd.as of 30 Jun 20241.99m0.79%
China Asset Management Co., Ltd.as of 30 Jun 20241.39m0.55%
Da Cheng Fund Management Co., Ltd.as of 30 Jun 20241.37m0.54%
Western Leadbank Fund Management Co., Ltdas of 30 Jun 2024149.80k0.06%
JX Asset Management Co.,Ltdas of 30 Jun 202490.00k0.04%
Truvalue Asset Management Co. Ltd.as of 30 Jun 202467.20k0.03%
Springs Fund Management Co. Ltd.as of 30 Jun 202418.40k0.01%
ICBC Credit Suisse Asset Management Co., Ltd.as of 30 Jun 20249.70k0.00%
Minsheng Royal Fund Management Co., Ltd.as of 30 Jun 20241.60k0.00%
Great Wall Fund Management Co., Ltd.as of 30 Jun 202473.000.00%
More ▼
Data from 30 Jun 2024 - 27 Sep 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.